Login to Your Account

Flx adds GV in $60M series C, moves CCR4 antagonist to clinic

By Marie Powers
News Editor

Thursday, December 21, 2017

Flx Bio Inc. completed a $60 million series C, adding GV (formerly Google Ventures) and several undisclosed investors to its syndicate. Existing investors, including the Column Group, Kleiner Perkins, Topspin Partners and Celgene Corp., also joined the round.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription